Oral Mucosal Vaccination against HIV Infection (R01)

The summary for the Oral Mucosal Vaccination against HIV Infection (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Oral Mucosal Vaccination against HIV Infection (R01): Purpose. This FOA issued by the NIDCR, NIH, solicits R01 applications that focus on harnessing oral mucosal and innate immunity to develop prophylactic HIV vaccines delivered through the oral mucosa. Specifically, the NIDCR is seeking applications that will address studies on the: 1) mechanisms linking oral mucosal and innate immunity with systemic adaptive immunity; 2) development of HIV vaccine antigens in oral expression vectors that are stable in the oral cavity and have the ability to trigger anti-HIV protective immunity; 3) mechanisms of HIV infection of target cells in the oral cavity (e.g., epithelial cells and immune cells) and effects of oral dendritic (DC),and natural killer (NK) cell subset changes during disease progression or upon oral mucosal HIV vaccination; 4) DC-NK cells cross-talk in the oral cavity and relationship to systemic adaptive immunity upon oral mucosal HIV vaccination; 5) similarities and differences between DC-NK cells cross-talk in the oral mucosal site compared with other mucosal sites, and 6) characterization of soluble defense molecules produced in oral secretions upon oral mucosal HIV vaccination. This FOA welcomes applications that further develop already characterized target vaccine antigens and formulations and relevant model antigens for oral delivery, target validation and early preclinical evaluation in relevant animal models. This FOA will not support basic vaccine antigen discovery, HIV vaccine clinical trials, projects on enteric vaccines for oral delivery, projects on nasal delivery methods for oral mucosal HIV vaccines, or therapeutic vaccine research. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. Funds Available and Anticipated Number of Awards. NIDCR intends to commit approximately $2 million in total costs (Direct costs plus Facilities and Administrative costs) in fiscal year 2010 through this announcement to support approximately 4-6 awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Federal Grant Title:	Oral Mucosal Vaccination against HIV Infection (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DE-10-001
Type of Funding:	Grant
CFDA Numbers:	93.121
CFDA Descriptions:	Oral Diseases and Disorders Research
Current Application Deadline:	Dec 02, 2009
Original Application Deadline:	Dec 02, 2009
Posted Date:	Jul 07, 2009
Creation Date:	Jul 07, 2009
Archive Date:	Jan 02, 2010
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research ...; • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...; • NIDCR Mentoring Network to Promote a Diverse Dental, Oral and Craniofacial Research Workfo...; • Epidemiological and Behavioral Research in Oral Health; • Metagenomic Analyses of the Oral Microbiome; • Phase Iii Clinical Trials in Oral Infectious Diseases
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...